EXACT Sciences Co. (EXAS) Short Interest Update

EXACT Sciences Co. (NASDAQ:EXAS) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 14,082,706 shares, a growth of 11.2% from the February 15th total of 12,660,709 shares. Based on an average daily trading volume, of 3,649,545 shares, the short-interest ratio is currently 3.9 days. Currently, 14.8% of the shares of the stock are sold short.

Shares of EXAS traded down $1.53 during midday trading on Monday, reaching $38.80. The company had a trading volume of 2,357,125 shares, compared to its average volume of 3,005,030. EXACT Sciences has a 1-year low of $22.18 and a 1-year high of $63.60. The company has a market capitalization of $4,877.57, a PE ratio of -39.19 and a beta of 0.87. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. The business had revenue of $87.41 million during the quarter, compared to the consensus estimate of $87.42 million. EXACT Sciences had a negative return on equity of 24.13% and a negative net margin of 43.01%. The company’s revenue for the quarter was up 148.0% on a year-over-year basis. During the same period last year, the company earned ($0.34) EPS. equities analysts anticipate that EXACT Sciences will post -0.86 earnings per share for the current fiscal year.

In other EXACT Sciences news, insider Kevin T. Conroy sold 125,402 shares of the firm’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $52.79, for a total value of $6,619,971.58. Following the transaction, the insider now owns 955,454 shares in the company, valued at approximately $50,438,416.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Maneesh Arora sold 12,352 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $42.34, for a total value of $522,983.68. Following the completion of the transaction, the chief operating officer now owns 644,621 shares in the company, valued at approximately $27,293,253.14. The disclosure for this sale can be found here. Insiders have sold a total of 449,538 shares of company stock worth $21,878,668 in the last quarter. Insiders own 4.00% of the company’s stock.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of EXACT Sciences by 1.7% during the 4th quarter. BlackRock Inc. now owns 7,658,145 shares of the medical research company’s stock worth $402,358,000 after purchasing an additional 126,513 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new stake in shares of EXACT Sciences during the 4th quarter worth about $66,280,000. Victory Capital Management Inc. increased its position in shares of EXACT Sciences by 82.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock worth $62,499,000 after purchasing an additional 539,160 shares during the last quarter. Geode Capital Management LLC increased its position in shares of EXACT Sciences by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,098,640 shares of the medical research company’s stock worth $57,722,000 after purchasing an additional 24,614 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of EXACT Sciences by 5.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 765,522 shares of the medical research company’s stock worth $40,221,000 after purchasing an additional 41,784 shares during the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on EXAS. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a report on Tuesday, January 16th. William Blair restated a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. BidaskClub upgraded EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Robert W. Baird upgraded EXACT Sciences from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $42.56 to $56.00 in a report on Tuesday, February 27th. Finally, Goldman Sachs started coverage on EXACT Sciences in a report on Monday, January 29th. They issued a “neutral” rating and a $51.00 price objective on the stock. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $52.84.

WARNING: “EXACT Sciences Co. (EXAS) Short Interest Update” was first reported by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://theenterpriseleader.com/2018/04/02/exact-sciences-co-exas-sees-large-increase-in-short-interest.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply